Kato Atsunaga, Kato Hideaki, Hirashima Noboru, Sakamoto Tomoyuki, Nukaya Haruhiko, Ito Kiyoaki, Matsunaga Seijiro, Kondo Hiromu, Tanaka Yoshito, Sakakibara Kenji
Department of Gastroenterology, Social Insurance Chukyo Hospital.
Nihon Shokakibyo Gakkai Zasshi. 2004 Nov;101(11):1209-16.
The relationship between Helicobacter pylori (H. pylori) and gastric diseases (e.g. peptic ulcer, MALT lymphoma, and stomach cancer) has been widely accepted. Recent studies have also suggested an association between H. pylori infection and idiopathic thrombocytopenic purpura (ITP). In this study, an H. pylori eradication treatment was administered to 20 ITP patients and elucidated for its effectiveness. Among those 20 patients, H. pylori infection was confirmed in 17 (85%) through a C14 urea breath test, a rapid urease test, or a culture examination of a biopsied sample obtained by gastrointestinal endoscopy. Although the other 3 were negative to H. pylori, the H. pylori eradication treatment was also attempted because no other effective treatments had been established at the time of this study. In the H. pylori eradication treatment, lansoprazole (LPZ) 60 mg bid, amoxicillin (AMPC) 1500 mg bid, and clarithromycin (CAM) 400 mg bid were given to each patient for 7 days. For 4 cases, CAM was replaced with metronidazole (MNZ) 750 mg bid. The patients whose H. pylori infection was not eradicated after the first treatment received the re-eradication treatment with LPZ 60 mg bid, AMPC 1500 mg bid, and MNZ 750 mg bid for 7 days. After the treatments, the success of eradicating H. pylori was confirmed in all 17 H. pylori positive patients. In addition, platelet recovery was obtained in 11/20 patients (55%), which included 2 H. pylori negative patients and 2 patients whose H. pylori eradication was not successful after the first treatment. No relationship was found between the eradication effectiveness and the following clinical parameters: age, gender, previous therapies, disease duration, presence of anti-nucleus antibody, endoscopic atrophic change in the stomach, or kinds of antibiotics used for the treatment. These results support the efficacy of an H. pylori eradication treatment for ITP patients. A noteworthy result of this study was that an increase of platelet count was observed not only in H. pylori positive ITP patients, but also in 2 out of 3 H. pylori negative ITP patients after H. pylori eradication. Further studies are required to elucidate the efficacy of H. pylori eradication therapy in the patients negative for H. pylori.
幽门螺杆菌(H. pylori)与胃部疾病(如消化性溃疡、黏膜相关淋巴组织淋巴瘤和胃癌)之间的关系已被广泛认可。最近的研究还表明,幽门螺杆菌感染与特发性血小板减少性紫癜(ITP)之间存在关联。在本研究中,对20例ITP患者进行了幽门螺杆菌根除治疗,并对其有效性进行了阐明。在这20例患者中,通过C14尿素呼气试验、快速尿素酶试验或经胃肠内镜获取的活检样本培养检查,确认17例(85%)存在幽门螺杆菌感染。尽管另外3例幽门螺杆菌检测为阴性,但由于在本研究开展时尚未确立其他有效治疗方法,因此也尝试了幽门螺杆菌根除治疗。在幽门螺杆菌根除治疗中,给予每位患者兰索拉唑(LPZ)60 mg,每日2次,阿莫西林(AMPC)1500 mg,每日2次,克拉霉素(CAM)400 mg,每日2次,持续7天。对于4例患者,将CAM替换为甲硝唑(MNZ)750 mg,每日2次。首次治疗后幽门螺杆菌感染未根除的患者接受再次根除治疗,使用LPZ 60 mg,每日2次,AMPC 1500 mg,每日2次,MNZ 750 mg,每日2次,持续7天。治疗后,所有17例幽门螺杆菌阳性患者均确认幽门螺杆菌根除成功。此外,20例患者中有11例(55%)血小板恢复,其中包括2例幽门螺杆菌阴性患者和2例首次治疗后幽门螺杆菌根除未成功的患者。未发现根除有效性与以下临床参数之间存在关联:年龄、性别、既往治疗、病程、抗核抗体的存在、胃内镜下萎缩性改变或治疗所用抗生素种类。这些结果支持幽门螺杆菌根除治疗对ITP患者的疗效。本研究一个值得注意的结果是,不仅在幽门螺杆菌阳性的ITP患者中观察到血小板计数增加,而且在幽门螺杆菌阴性的3例ITP患者中有2例在幽门螺杆菌根除后血小板计数增加。需要进一步研究以阐明幽门螺杆菌根除疗法对幽门螺杆菌阴性患者的疗效。